Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Annexon (Nasdaq: ANNX) announced that CEO Douglas Love will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET.
A live webcast will be available on the company's Investors "Events & Presentations" page and a replay will be archived on the Annexon website for 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – ANNX
In the Apr 9 session, ANNX gained 1.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings update | Positive | +11.7% | Reported 2025 results, cash runway and key 2026 clinical milestones. |
| Mar 16 | Inducement grant | Neutral | -1.9% | Inducement stock option grant to a new employee under plan. |
| Feb 24 | Conference presentation | Neutral | +1.4% | Announcement of participation at TD Cowen healthcare conference. |
| Feb 17 | KOL event | Neutral | +3.1% | Planned KOL event focused on vonaprument and ARCHER II trial. |
| Jan 16 | Inducement grants | Neutral | +1.5% | Inducement equity awards to two new non-executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history shows a strong positive move on earnings, while routine corporate or event-related updates have seen modest, mixed reactions.
Over recent months, Annexon has balanced routine corporate updates with more material pipeline and financial disclosures. The Mar 30 earnings and pipeline update coincided with a +11.69% move, supported by $238.3M in cash and runway into H2 2027. In contrast, inducement grants on Jan 16 and Mar 16 and conference announcements in February drew only small price changes. Today’s Needham conference appearance fits the pattern of informational investor outreach rather than a defined clinical or financial catalyst.
Key Terms
neuroinflammatory diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to millions of patients to help them live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com
